.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cerilliant
UBS
Medtronic
Argus Health
Federal Trade Commission
Farmers Insurance
Deloitte
Covington
Fuji

Generated: December 15, 2017

DrugPatentWatch Database Preview

XTAMPZA ER Drug Profile

« Back to Dashboard

Which patents cover Xtampza Er, and what generic alternatives are available?

Xtampza Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. There are twelve patents protecting this drug.

This drug has fourteen patent family members in five countries and one supplementary protection certificate in one country.

The generic ingredient in XTAMPZA ER is oxycodone. There are seventeen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxycodone profile page.
Drug patent expirations by year for XTAMPZA ER

Pharmacology for XTAMPZA ER

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

Medical Subject Heading (MeSH) Categories for XTAMPZA ER

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-004Apr 26, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-003Apr 26, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-004Apr 26, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-005Apr 26, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-004Apr 26, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-004Apr 26, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-005Apr 26, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-005Apr 26, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-003Apr 26, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Collegium Pharm IncXTAMPZA ERoxycodoneCAPSULE, EXTENDED RELEASE;ORAL208090-003Apr 26, 2016RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XTAMPZA ER

Country Document Number Estimated Expiration
Japan2009298822► Subscribe
Japan2015166402► Subscribe
European Patent Office1594467► Subscribe
Australia2003247876► Subscribe
World Intellectual Property Organization (WIPO)2004004693► Subscribe
Japan2017101075► Subscribe
European Patent Office1765292► Subscribe
World Intellectual Property Organization (WIPO)2005123039► Subscribe
Japan2013216707► Subscribe
Japan4694207► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: XTAMPZA ER

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
US Army
Chinese Patent Office
Mallinckrodt
Moodys
Harvard Business School
UBS
Daiichi Sankyo
Fuji
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot